[
    [
        {
            "time": "",
            "original_text": "“调仓”成机构四季度主基调，阳光私募基金现身21股",
            "features": {
                "keywords": [
                    "调仓",
                    "机构",
                    "四季度",
                    "阳光私募基金"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "“调仓”成机构四季度主基调，阳光私募基金现身21股",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "[增持评级]医药生物行业周报：2018年新气象 新医药 看好商业健康险和创新药物的快速发展",
            "features": {
                "keywords": [
                    "医药生物",
                    "商业健康险",
                    "创新药物",
                    "增持评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级]医药生物行业周报：2018年新气象 新医药 看好商业健康险和创新药物的快速发展",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "[增持评级]上海证券医药生物行业周报20180213",
            "features": {
                "keywords": [
                    "医药生物",
                    "上海证券",
                    "增持评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级]上海证券医药生物行业周报20180213",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "长春高新点评报告:生长激素保持快速增长,行业未来空间广阔",
            "features": {
                "keywords": [
                    "长春高新",
                    "生长激素",
                    "快速增长",
                    "行业空间"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "长春高新点评报告:生长激素保持快速增长,行业未来空间广阔",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医药生物：建议配置超跌优质公司",
            "features": {
                "keywords": [
                    "医药生物",
                    "超跌",
                    "优质公司"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物：建议配置超跌优质公司",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "社保斥资近8亿元增持5只个股 机构扎堆推荐3只龙头股",
            "features": {
                "keywords": [
                    "社保",
                    "增持",
                    "龙头股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "社保斥资近8亿元增持5只个股 机构扎堆推荐3只龙头股",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "中德证券有限责任公司关于长春高新技术产业(集团)股份有限公司2017年度保荐工作报告",
            "features": {
                "keywords": [
                    "中德证券",
                    "长春高新",
                    "保荐工作"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "中德证券有限责任公司关于长春高新技术产业(集团)股份有限公司2017年度保荐工作报告",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报:看好估值合理的子行业龙头,重点推荐恒瑞医药、长春高新、美年健康等",
            "features": {
                "keywords": [
                    "医药生物",
                    "估值合理",
                    "子行业龙头",
                    "恒瑞医药",
                    "长春高新",
                    "美年健康"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报:看好估值合理的子行业龙头,重点推荐恒瑞医药、长春高新、美年健康等",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]